Cook Medical Brings Advanced Endovascular Thoracic Aneurysm Treatment To Canadians

Main Category: Vascular
Article Date: 22 May 2009 - 4:00 PDT

email to a friend   printer friendly   opinions  

In a move reflecting the rapid acceptance of Cook Medical's advanced endogaft for thoracic aortic aneurysm worldwide, the company has received approval to market the Zenith TX2® TAA Endovascular Graft in Canada. Globally, the Zenith TX2 Endovascular Graft is now available in more than 60 markets, including the United States, Canada, the United Kingdom, European Union, Australia and others internationally.

"Physicians around the world have made Cook's Zenith AAA Endograft the world's best-selling device of its kind, and we're now seeing similar momentum in the growing market for endovascular treatment of thoracic aortic aneurysms," said Phil Nowell, global leader of Cook's aortic intervention business unit.

One of Canada's leading endovascular specialists, Cherrie Abraham, M.D., Department of Vascular Surgery, Jewish General Hospital at McGill University, Montreal, Quebec, said: "This approval is a recognition that this is an excellent graft that is here to stay. The biggest advantage with TX2 is the control offered by the tri-fold proximal end. With TX2, we now have the ability to deploy a graft without the wind-sock effect that is seen with other commercially approved thoracic stent grafts. I also like that even after unsheathing the graft, you still have the ability to advance it proximally, again because of the constrained top end."

U.S. sales of Cook's TX2 Endograft have increased every month since it received FDA clearance in June 2008. During that period, approximately 1,000 physicians at nearly 400 hospitals in the U.S. have requested and received training in the appropriate use of the TX2, making them eligible to bring the advanced benefits of this device to numerous patients suffering thoracic aortic aneurysms.

"With sales of the Zenith TX2 Endograft accelerating each month, and the recent CE Mark approval for our next-generation TX2 Endograft with Pro-Form*, we believe Cook is on track to achieve market leadership in thoracic aneurysms, as well."

Just as it is in the United States, the Zenith TX2 Endograft is indicated for the endovascular treatment of patients with aneurysms or ulcers of the descending thoracic aorta having vascular morphology suitable for endovascular repair.

* The TX2 Endograft with Pro-Form is not available for sale in the U.S. or Canada.

Source
Cook Medical

• Additional
• References
• Citations